SNY Stock Recent News

Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.

Sanofi (NASDAQ: SNY ) layoffs are in the news Monday after the therapeutic solutions company announced changes to how it will handle research and development going forward. Sanofi wants to focus more on Phase 3 clinical trials and will be reducing its other R&D projects.

Sanofi has reached an agreement in principle to settle 4,000 lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Sanofi has underperformed the U.S. stock market lately but now offers one of the smartest growth-at-a-reasonable-price setups in Big Pharma. Sanofi is best known for its patented drug Dupixent and numerous vaccines manufactured for global use, which generate a significant portion of its revenue. The company has a stable dividend proposition, strong balance sheet, and better-than-average potential for earnings growth in the future.

Sanofi (SNY) Leerink Partners Global Biopharma Conference (Transcript)

Drugmaker Sanofi's consumer healthcare division has attracted interest from private equity funds as the French group prepares to spin out the business, two sources close to the matter told Reuters.

Denali Therapeutics said on Friday it was informed by partner Sanofi that their drug for a type of neurological disease did not meet the main goal in a mid-stage trial.

Sanofi (SNY) Q4 2023 Earnings Call Transcript

TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.

Sanofi's fourth-quarter operating income declined 5% as a weaker U.S. dollar and cheaper rivals competing against its established multiple sclerosis drug outweighed growing sales of anti-inflammatory drug Dupixent.